WO2008084710A1 - ヘルペスウィルス感染阻害剤、ヘルペスウィルスの感染阻害方法およびその利用 - Google Patents
ヘルペスウィルス感染阻害剤、ヘルペスウィルスの感染阻害方法およびその利用 Download PDFInfo
- Publication number
- WO2008084710A1 WO2008084710A1 PCT/JP2007/075096 JP2007075096W WO2008084710A1 WO 2008084710 A1 WO2008084710 A1 WO 2008084710A1 JP 2007075096 W JP2007075096 W JP 2007075096W WO 2008084710 A1 WO2008084710 A1 WO 2008084710A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- herpesvirus infection
- inhibitor
- inhibition
- glycoprotein
- herpesvirus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/522,651 US20100129347A1 (en) | 2007-01-12 | 2007-12-27 | Herpes virus infection inhibitor, method for inhibiting infection with herpes virus, and use thereof |
CA2675025A CA2675025C (en) | 2007-01-12 | 2007-12-27 | Inhibitor of herpesvirus infection, method for inhibition of herpesvirus infection, and use thereof |
EP07860318A EP2127672A4 (en) | 2007-01-12 | 2007-12-27 | INHIBITORS OF HERPESVIRUS INFECTION, METHOD FOR INHIBITING HERPESVIRUS INFECTION AND ITS USE |
JP2008553072A JP4997649B2 (ja) | 2007-01-12 | 2007-12-27 | ヘルペスウィルス感染阻害剤、およびヘルペスウィルスの感染阻害の確認方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-005229 | 2007-01-12 | ||
JP2007005229 | 2007-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008084710A1 true WO2008084710A1 (ja) | 2008-07-17 |
Family
ID=39608604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/075096 WO2008084710A1 (ja) | 2007-01-12 | 2007-12-27 | ヘルペスウィルス感染阻害剤、ヘルペスウィルスの感染阻害方法およびその利用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20100129347A1 (ja) |
EP (1) | EP2127672A4 (ja) |
JP (1) | JP4997649B2 (ja) |
CA (1) | CA2675025C (ja) |
WO (1) | WO2008084710A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011118779A1 (ja) | 2010-03-26 | 2011-09-29 | 国立大学法人東京大学 | ヘルペスウイルス感染症の治療または予防のための医薬組成物 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011084357A1 (en) * | 2009-12-17 | 2011-07-14 | Schering Corporation | Modulation of pilr to treat immune disorders |
WO2012088383A2 (en) | 2010-12-23 | 2012-06-28 | Genentech, Inc. | PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME |
WO2019126472A1 (en) * | 2017-12-22 | 2019-06-27 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
BR112022016368A2 (pt) * | 2020-02-18 | 2023-01-10 | Alector Llc | Anticorpos pilra e seus métodos de uso |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007099921A1 (ja) * | 2006-02-28 | 2007-09-07 | Osaka University | PILRαと結合するポリペプチド、およびそれをコードするポリヌクレオチド、並びにその利用 |
-
2007
- 2007-12-27 CA CA2675025A patent/CA2675025C/en not_active Expired - Fee Related
- 2007-12-27 JP JP2008553072A patent/JP4997649B2/ja active Active
- 2007-12-27 EP EP07860318A patent/EP2127672A4/en not_active Withdrawn
- 2007-12-27 US US12/522,651 patent/US20100129347A1/en not_active Abandoned
- 2007-12-27 WO PCT/JP2007/075096 patent/WO2008084710A1/ja active Search and Examination
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007099921A1 (ja) * | 2006-02-28 | 2007-09-07 | Osaka University | PILRαと結合するポリペプチド、およびそれをコードするポリヌクレオチド、並びにその利用 |
Non-Patent Citations (22)
Title |
---|
CO M.S. ET AL.: "Humanized antibodies for antiviral therapy", PROC. NATL. ACAD. SCI. USA, vol. 88, no. 7, 1991, pages 2869 - 2873, XP000200583 * |
DUUS K.M. ET AL.: "Wild-type Kaposi's sarcoma-associated herpesvirus isolated from the oropharynx of immune-competent individuals has tropism for cultured oral epithelial cells", J. VIROL., vol. 78, no. 8, 2004, pages 4074 - 4084, XP008109996 * |
F.C.BENDER, J.C. ET AL., J. BIOL., vol. 79, 2005, pages 11588 |
FOURNIER N. ET AL.: "FDF03, a novel inhibitory receptor of the immunoglobulin superfamily, is expressed by human dendritic and myeloid cells", J. IMMUNOL., vol. 165, no. 3, 2000, pages 1197 - 1209, XP008109997 * |
FOURNIER, N. ET AL., J. IMMUNOL., vol. 165, 2000, pages 1197 - 209 |
FURTHER: "recently, there has been reported a herpes virus resistant to acyclovir", TRENDS MICROBIOL., vol. 2, 1994, pages 481 |
H.ARASE ET AL., SCIENCE, vol. 296, 2002, pages 1323 |
HARLOW ET AL.: "Antibodies: A laboratory manual", 1988, COLD SPRING HARBOR LABORATORY |
I. SHIRATORI ET AL., J. IMMUNOL., vol. 175, 2005, pages 4441 |
I.SHIRATORI ET AL., J.EXP. MED., vol. 199, 2004, pages 525 |
IWASAKI ET AL., MONOCLONAL ANTIBODY HYBRIDOMA AND ELISA, 1991 |
MIKLOSKA Z. ET AL.: "Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro", J. VIROL., vol. 73, no. 7, 1999, pages 5934 - 5944, XP008109994 * |
MOUSSEAU D. D. ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 4467 - 4474 |
MOUSSEAU D.D. ET AL.: "PILRalpha, a novel immunoreceptor tyrosine-based inhibitory motif-bearing protein, recruits SHP-1 upon tyrosine phosphorylation and is paired with the truncated counterpart PILRbeta", J. BIOL. CHEM., vol. 275, no. 6, 2000, pages 4467 - 4474, XP002518533 * |
R.I.MONTGOMERY ET AL., CELL, vol. 87, 1996, pages 427 |
R.J.GERAGHTY ET AL., SCIENCE, vol. 280, 1998, pages 1618 |
SATOH T. ET AL.: "HSV-1 infection through inhibitory receptor, PILRalpha", PROCEEDINGS OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, vol. 37, 25 October 2007 (2007-10-25), pages 78, XP008110730 * |
SATOH T. ET AL.: "Tanjun Herpes Virus Type i no Pair-gata Receptor (PILR) o Kaishita Aratana Men'eki Seigyo Kiko", PROCEEDINGS OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, vol. 36, 2006, pages 257, XP008110732 * |
See also references of EP2127672A4 * |
SHIRATORI I. ET AL.: "Activation of natural killer cells and dendritic cells upon recognition of a novel CD99-like ligand by paired immunoglobulin-like type 2 receptor", J. EXP. MED., vol. 199, no. 4, 2004, pages 525 - 533, XP003016887 * |
SHIRATORI, I. ET AL., J. EXP. MED., vol. 199, 2004, pages 525 - 533 |
WANG J. ET AL.: "Recognition of Glycoprotein B of Herpes Simplex Virus-I by Inhibitory PILRalpha", PROCEEDINGS OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, vol. 37, 25 October 2007 (2007-10-25), pages 197, XP008110731 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011118779A1 (ja) | 2010-03-26 | 2011-09-29 | 国立大学法人東京大学 | ヘルペスウイルス感染症の治療または予防のための医薬組成物 |
CN102985112A (zh) * | 2010-03-26 | 2013-03-20 | 国立大学法人东京大学 | 用于治疗或预防疱疹病毒感染症的医药组合物 |
Also Published As
Publication number | Publication date |
---|---|
JP4997649B2 (ja) | 2012-08-08 |
CA2675025A1 (en) | 2008-07-17 |
CA2675025C (en) | 2012-02-21 |
JPWO2008084710A1 (ja) | 2010-04-30 |
EP2127672A1 (en) | 2009-12-02 |
US20100129347A1 (en) | 2010-05-27 |
EP2127672A4 (en) | 2011-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008115281A3 (en) | Compounds for treating viral infections | |
WO2008051416A3 (en) | Compounds that inhibit the activity of hsp90 for treating infections | |
WO2010123919A3 (en) | Piperidine inhibitors of janus kinase 3 | |
MX2010009982A (es) | Revestimiento hidrofílico. | |
WO2010060937A3 (en) | Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor | |
WO2009042114A3 (en) | Phenazine derivatives and uses thereof | |
IL195279A0 (en) | 1,5-diphenylpyrazoles ii as hsp90 inhibitors | |
PL2029642T3 (pl) | Kompozycja katalizatora do kopolimeryzacji propylenu | |
WO2006034035A3 (en) | Treatment of ischemia | |
GB0912562D0 (en) | LXR-antagonists for the prevention, reduction or inhibition of scarring | |
WO2009004593A3 (en) | Processes for the preparation of epinephrine | |
WO2011005052A8 (en) | Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same | |
WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
WO2008084710A1 (ja) | ヘルペスウィルス感染阻害剤、ヘルペスウィルスの感染阻害方法およびその利用 | |
WO2009051223A1 (ja) | 白内障処置のための医薬組成物 | |
WO2006069159A3 (en) | Pharmaceutical compositions comprising amorphous benzimidazole compounds | |
WO2010098583A2 (ko) | 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물 | |
WO2009154739A3 (en) | Smoothened receptor modulators | |
WO2010005148A3 (en) | Novel isoindolinone derivatives having inhibitory activity against t-type calcium channel and method for preparation thereof | |
WO2009111218A3 (en) | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same | |
WO2008059519A3 (en) | A process for the preparation of intermediates of rosuvastatin | |
EP2048166A4 (en) | TITANIUM SOLID CATALYST INGREDIENT, OLEFIN POLYMERIZATION CATALYST, AND OLEFIN POLYMERIZATION PROCESS | |
EP2007391B8 (en) | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315ile kinase inhibitor | |
WO2010059639A3 (en) | Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv | |
WO2010075086A3 (en) | Pyrrolidinone inhibitors of pde-4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07860318 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008553072 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2675025 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007860318 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12522651 Country of ref document: US |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |